Köhler Chemie

Dr. Franz Josef Köhler established Dr. Franz Köhler Chemie GmbH in 1959.

As early as in 1965, Dr. Franz Köhler Chemie GmbH developed CARDIOPLEGIN®, the world’s first approved cardioplegic drug (1972 to 1997), which stops the heart temporarily through hypermagnesemia. At that time, it was a completely new method to better protect heart muscles. According to the usual procedure, the cardiac arrest was induced through hyperkalemia.

From 1973, together with Professor Dr. H.-J. Bretschneider (1922 to 1993) from Göttingen, Dr. Franz Köhler Chemie GmbH started the research for developing an organ-protecting solution with outstanding properties, a solution that would be incomparable to other organ-protecting solutions due to its universal application. CUSTODIOL^® is suitable for ‘in situ’ open heart surgery and also for kidney perfusion for blood free tumor resection as well as for the removal of multiple organs during organ transplantation. In more than 100 countries, CUSTODIOL^® is applied for the mentioned indications. Based on its numerous superior advantages, the solution has gained a high reputation in heart surgery and transplant medicine. It wasn’t until the early 1980s that cardiac arrest was carried out using cardio protection with CUSTODIOL^® (HTK solution according to Bretschneider).

Dr. Franz Köhler Chemie GmbH has now expanded into Asia with a new Joint Venture, Koehler Pharmaceutical Asia Pte Ltd (KPA), in Singapore. Eshcol Pharmaceutical Group (S) Pte Ltd, has been representing Dr. Franz Köhler Chemie GmbH for the past 21 years and will continue to work alongside KPA to further establish Dr. Franz Köhler Chemie GmbH products in Singapore.

For more information on Dr. Franz Köhler Chemie GmbH products, please email us at contact@epg.com.sg
‍